RYTHMOL SR
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Sep 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 57m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYTHMOL SR (propafenone) is an extended-release oral antiarrhythmic agent used to maintain normal heart rhythm in patients with atrial fibrillation and other cardiac arrhythmias. It is a Class IC antiarrhythmic that works by blocking sodium channels and slowing conduction velocity in the heart. The drug has been approved since 2003 and represents a mature treatment option in the antiarrhythmic class.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30); team size likely stable or contracting as LOE approaches.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioequivalence of RYTHMOL SR® Manufactured at Two Different Sites
Started Apr 2012
38 enrolled
Arrhythmia, Cardiac
Career Relevance
Working on RYTHMOL SR offers experience in mature product management and competitive positioning in a crowded therapeutic class. This role is best suited for professionals skilled in lifecycle management, defending market share, and preparing for generic transition rather than innovation-focused careers.
Brand Manager
Worked on RYTHMOL SR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.